Mantle Cell Lymphoma

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Latest News

BTK Inhibitor Failure Signals Unmet Need for a Standard of Care in Relapsed/Refractory MCL
BTK Inhibitor Failure Signals Unmet Need for a Standard of Care in Relapsed/Refractory MCL

November 18th 2022

Improved mantle cell lymphoma treatments are necessary for patients who have relapsed on or are refractory to BTK inhibitors, according to findings from SCHOLAR-2, a multicenter, retrospective chart review of European patients with MCL who relapsed following or were intolerant to BTK inhibitors.

Ibrutinib Demonstrates Real-world ORR Benefit in Relapsed/Refractory MCL
Ibrutinib Demonstrates Real-world ORR Benefit in Relapsed/Refractory MCL

November 17th 2022

Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL
Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL

October 20th 2022

Treatments for MCL Continue to Progress
Treatments for MCL Continue to Progress

October 14th 2022

Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL
Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL

October 10th 2022

Video Series
Video Interviews
Podcasts

More News